Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 17066
Country/Region: Uganda
Year: 2018
Main Partner: World Vision
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USAID
Total Funding: $279,189 Additional Pipeline Funding: $710,034

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $24,577
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $9,342
Care: Pediatric Care and Support (PDCS) $19,420
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $74,943
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $30,795
Sexual Prevention: Other Sexual Prevention (HVOP) $22,383
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $38,590
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $53,612
Treatment: Pediatric Treatment (PDTX) $5,527
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV <10, Female, Physical and/or Emotional Violence 2019 18
GEND_GBV <10, Female, Sexual Violence (Post-Rape Care) 2019 14
GEND_GBV <10, Male, Physical and/or Emotional Violence 2019 8
GEND_GBV <10, Male, Sexual Violence (Post-Rape Care) 2019 1
GEND_GBV 10-14, Female, Physical and/or Emotional Violence 2019 49
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2019 41
GEND_GBV 10-14, Male, Physical and/or Emotional Violence 2019 18
GEND_GBV 10-14, Male, Sexual Violence (Post-Rape Care) 2019 2
GEND_GBV 15-19, Female, Physical and/or Emotional Violence 2019 444
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2019 378
GEND_GBV 15-19, Male, Physical and/or Emotional Violence 2019 45
GEND_GBV 15-19, Male, Sexual Violence (Post-Rape Care) 2019 14
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2019 210
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2019 115
GEND_GBV 20-24, Male, Physical and/or Emotional Violence 2019 108
GEND_GBV 20-24, Male, Sexual Violence (Post-Rape Care) 2019 47
GEND_GBV 25-29, Female, Physical and/or Emotional Violence 2019 77
GEND_GBV 25-29, Female, Sexual Violence (Post-Rape Care) 2019 9
GEND_GBV 25-29, Male, Physical and/or Emotional Violence 2019 53
GEND_GBV 25-29, Male, Sexual Violence (Post-Rape Care) 2019 3
GEND_GBV 30-34, Female, Physical and/or Emotional Violence 2019 77
GEND_GBV 30-34, Female, Sexual Violence (Post-Rape Care) 2019 9
GEND_GBV 30-34, Male, Physical and/or Emotional Violence 2019 53
GEND_GBV 30-34, Male, Sexual Violence (Post-Rape Care) 2019 3
GEND_GBV 35-39, Female, Physical and/or Emotional Violence 2019 77
GEND_GBV 35-39, Female, Sexual Violence (Post-Rape Care) 2019 9
GEND_GBV 35-39, Male, Physical and/or Emotional Violence 2019 53
GEND_GBV 35-39, Male, Sexual Violence (Post-Rape Care) 2019 3
GEND_GBV 40-49, Female, Physical and/or Emotional Violence 2019 26
GEND_GBV 40-49, Female, Sexual Violence (Post-Rape Care) 2019 2
GEND_GBV 40-49, Male, Physical and/or Emotional Violence 2019 18
GEND_GBV 40-49, Male, Sexual Violence (Post-Rape Care) 2019 1
GEND_GBV 50+, Female, Physical and/or Emotional Violence 2019 54
GEND_GBV 50+, Female, Sexual Violence (Post-Rape Care) 2019 4
GEND_GBV 50+, Male, Physical and/or Emotional Violence 2019 36
GEND_GBV 50+, Male, Sexual Violence (Post-Rape Care) 2019 2
GEND_GBV By PEP service provision (related to sexual violence services provided) 2019 199
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2019 1,422
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2019 659
GEND_GBV Number of people receiving post-GBV care 2019 2,081
HTS_SELF 15-19, Female, Directly-Assisted 2019 7
HTS_SELF 15-19, Female, Unassisted 2019 19
HTS_SELF 20-24, Female, Directly-Assisted 2019 19
HTS_SELF 20-24, Female, Unassisted 2019 57
HTS_SELF 20-24, Male, Directly-Assisted 2019 1
HTS_SELF 20-24, Male, Unassisted 2019 1
HTS_SELF 25-29, Female, Directly-Assisted 2019 11
HTS_SELF 25-29, Female, Unassisted 2019 38
HTS_SELF 25-29, Male, Directly-Assisted 2019 1
HTS_SELF 25-29, Male, Unassisted 2019 1
HTS_SELF 30-34, Female, Directly-Assisted 2019 6
HTS_SELF 30-34, Female, Unassisted 2019 15
HTS_SELF 35-39, Female, Directly-Assisted 2019 3
HTS_SELF 35-39, Female, Unassisted 2019 8
HTS_SELF 40-49, Female, Directly-Assisted 2019 1
HTS_SELF 40-49, Female, Unassisted 2019 2
HTS_SELF FSW, Directly-Assisted 2019 10
HTS_SELF FSW, Unassisted 2019 29
HTS_SELF MSM, Directly-Assisted 2019 2
HTS_SELF MSM, Unassisted 2019 2
HTS_SELF Unassisted - Sex Partner 2019 191
HTS_TST <5, Unknown Sex, Negative 2019 9
HTS_TST <5, Unknown Sex, Negative 2019 1
HTS_TST 15-19, Female, Negative 2019 6
HTS_TST 15-19, Male, Negative 2019 1
HTS_TST 20-24, Female, Negative 2019 9
HTS_TST 20-24, Male, Negative 2019 4
HTS_TST 25-29, Female, Negative 2019 2
HTS_TST 25-29, Female, Negative 2019 194
HTS_TST 25-29, Female, Negative 2019 828
HTS_TST 25-29, Female, Negative 2019 13
HTS_TST 25-29, Female, Negative 2019 4
HTS_TST 25-29, Female, Negative 2019 1
HTS_TST 25-29, Female, Negative 2019 8
HTS_TST 25-29, Female, Negative 2019 1
HTS_TST 25-29, Female, Negative 2019 23
HTS_TST 25-29, Male, Negative 2019 1
HTS_TST 25-29, Male, Negative 2019 202
HTS_TST 25-29, Male, Negative 2019 7
HTS_TST 25-29, Male, Negative 2019 2
HTS_TST 25-29, Male, Negative 2019 2,523
HTS_TST 25-29, Male, Negative 2019 1
HTS_TST 25-29, Male, Negative 2019 8
HTS_TST 25-29, Male, Negative 2019 1,523
HTS_TST 25-29, Male, Negative 2019 20
HTS_TST 30-34, Female, Negative 2019 1
HTS_TST 30-34, Female, Negative 2019 70
HTS_TST 30-34, Female, Negative 2019 359
HTS_TST 30-34, Female, Negative 2019 6
HTS_TST 30-34, Female, Negative 2019 4
HTS_TST 30-34, Female, Negative 2019 1
HTS_TST 30-34, Female, Negative 2019 2
HTS_TST 30-34, Female, Negative 2019 1
HTS_TST 30-34, Female, Negative 2019 5
HTS_TST 30-34, Male, Negative 2019 1
HTS_TST 30-34, Male, Negative 2019 129
HTS_TST 30-34, Male, Negative 2019 6
HTS_TST 30-34, Male, Negative 2019 3
HTS_TST 30-34, Male, Negative 2019 336
HTS_TST 30-34, Male, Negative 2019 1
HTS_TST 30-34, Male, Negative 2019 5
HTS_TST 30-34, Male, Negative 2019 203
HTS_TST 30-34, Male, Negative 2019 15
HTS_TST 35-39, Female, Negative 2019 8
HTS_TST 35-39, Female, Negative 2019 1
HTS_TST 35-39, Female, Negative 2019 77
HTS_TST 35-39, Female, Negative 2019 372
HTS_TST 35-39, Female, Negative 2019 6
HTS_TST 35-39, Female, Negative 2019 5
HTS_TST 35-39, Female, Negative 2019 1
HTS_TST 35-39, Female, Negative 2019 3
HTS_TST 35-39, Female, Negative 2019 1
HTS_TST 35-39, Male, Negative 2019 17
HTS_TST 35-39, Male, Negative 2019 1
HTS_TST 35-39, Male, Negative 2019 146
HTS_TST 35-39, Male, Negative 2019 6
HTS_TST 35-39, Male, Negative 2019 9
HTS_TST 35-39, Male, Negative 2019 336
HTS_TST 35-39, Male, Negative 2019 1
HTS_TST 35-39, Male, Negative 2019 6
HTS_TST 35-39, Male, Negative 2019 203
HTS_TST 40-49, Female, Negative 2019 6
HTS_TST 40-49, Female, Negative 2019 63
HTS_TST 40-49, Female, Negative 2019 249
HTS_TST 40-49, Female, Negative 2019 4
HTS_TST 40-49, Female, Negative 2019 4
HTS_TST 40-49, Female, Negative 2019 2
HTS_TST 40-49, Male, Negative 2019 22
HTS_TST 40-49, Male, Negative 2019 1
HTS_TST 40-49, Male, Negative 2019 119
HTS_TST 40-49, Male, Negative 2019 6
HTS_TST 40-49, Male, Negative 2019 4
HTS_TST 40-49, Male, Negative 2019 336
HTS_TST 40-49, Male, Negative 2019 1
HTS_TST 40-49, Male, Negative 2019 4
HTS_TST 40-49, Male, Negative 2019 203
HTS_TST 50+, Male, Negative 2019 3
HTS_TST By Key Population: FSW, Negative 2019 194
HTS_TST By Key Population: MSM, Negative 2019 16
HTS_TST By Key Population: People in prisons and other enclosed settings, Negative 2019 4
HTS_TST By Key Population: People in prisons and other enclosed settings, Negative 2019 442
HTS_TST By Key Population: PWID, Negative 2019 18
HTS_TST By Key Population: TG, Negative 2019 2
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 5,203
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 14,315
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2019 1
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2019 716
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2019 2
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2019 1,242
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2019 1
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2019 5
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 1
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 4
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 1
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 4
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 2
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 6
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 6
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 6
HTS_TST Service Delivery Point (Facility) Inpatient: 1-9, Negative 2019 1
HTS_TST Service Delivery Point (Facility) Inpatient: 1-9, Negative 2019 1
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2019 1
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2019 1
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 1
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 1
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 1
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 1
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 1
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2019 8
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2019 48
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2019 9
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2019 52
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2019 2
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2019 11
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 3
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 79
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 2
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 41
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 4
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 121
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 5
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 129
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 2
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 55
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2019 12
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2019 73
HTS_TST Service Delivery Point (Facility) TB: 1-9, Negative 2019 4
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2019 1
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 5
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 7
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 9
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 4
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 2
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 5
HTS_TST Service Delivery Point (Facility) VMMC: 10-14, Negative 2019 254
HTS_TST Service Delivery Point (Facility) VMMC: 10-14, Negative 2019 420
HTS_TST Service Delivery Point (Facility) VMMC: 15-19, Negative 2019 1,269
HTS_TST Service Delivery Point (Facility) VMMC: 15-19, Negative 2019 2,101
HTS_TST Service Delivery Point (Facility) VMMC: 20-24, Negative 2019 1,269
HTS_TST Service Delivery Point (Facility) VMMC: 20-24, Negative 2019 2,101
HTS_TST Service Delivery Point (Facility) VMMC: 50+, Negative 2019 153
HTS_TST Service Delivery Point (Facility) VMMC: 50+, Negative 2019 252
HTS_TST_POS 25-29, Female, Positive 2019 6
HTS_TST_POS 25-29, Female, Positive 2019 25
HTS_TST_POS 25-29, Female, Positive 2019 1
HTS_TST_POS 25-29, Female, Positive 2019 3
HTS_TST_POS 25-29, Male, Positive 2019 6
HTS_TST_POS 25-29, Male, Positive 2019 1
HTS_TST_POS 25-29, Male, Positive 2019 13
HTS_TST_POS 25-29, Male, Positive 2019 6
HTS_TST_POS 25-29, Male, Positive 2019 2
HTS_TST_POS 30-34, Female, Positive 2019 2
HTS_TST_POS 30-34, Female, Positive 2019 17
HTS_TST_POS 30-34, Female, Positive 2019 1
HTS_TST_POS 30-34, Male, Positive 2019 2
HTS_TST_POS 30-34, Male, Positive 2019 4
HTS_TST_POS 30-34, Male, Positive 2019 1
HTS_TST_POS 30-34, Male, Positive 2019 1
HTS_TST_POS 30-34, Male, Positive 2019 1
HTS_TST_POS 35-39, Female, Positive 2019 1
HTS_TST_POS 35-39, Female, Positive 2019 2
HTS_TST_POS 35-39, Female, Positive 2019 6
HTS_TST_POS 35-39, Female, Positive 2019 1
HTS_TST_POS 35-39, Male, Positive 2019 2
HTS_TST_POS 35-39, Male, Positive 2019 4
HTS_TST_POS 35-39, Male, Positive 2019 2
HTS_TST_POS 35-39, Male, Positive 2019 1
HTS_TST_POS 35-39, Male, Positive 2019 1
HTS_TST_POS 40-49, Female, Positive 2019 2
HTS_TST_POS 40-49, Female, Positive 2019 1
HTS_TST_POS 40-49, Female, Positive 2019 1
HTS_TST_POS 40-49, Male, Positive 2019 3
HTS_TST_POS 40-49, Male, Positive 2019 3
HTS_TST_POS 40-49, Male, Positive 2019 1
HTS_TST_POS 40-49, Male, Positive 2019 1
HTS_TST_POS 40-49, Male, Positive 2019 1
HTS_TST_POS By Key Population: FSW, Positive 2019 94
HTS_TST_POS By Key Population: MSM, Positive 2019 4
HTS_TST_POS By Key Population: People in prisons and other enclosed settings, Positive 2019 1
HTS_TST_POS By Key Population: People in prisons and other enclosed settings, Positive 2019 83
HTS_TST_POS By Key Population: PWID, Positive 2019 3
HTS_TST_POS By Key Population: TG, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2019 21
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2019 34
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) TB: 1-9, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) VMMC: 10-14, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) VMMC: 10-14, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) VMMC: 15-19, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) VMMC: 15-19, Positive 2019 11
HTS_TST_POS Service Delivery Point (Facility) VMMC: 20-24, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) VMMC: 20-24, Positive 2019 11
HTS_TST_POS Service Delivery Point (Facility) VMMC: 50+, Positive 2019 1
PMTCT_ART Already on ART at beginning of current pregnancy 2019 225
PMTCT_ART New on ART 2019 97
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 322
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 4,096
PMTCT_EID By infants who received a virologic test within 2 months of birth 2019 269
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 53
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 322
PMTCT_EID Sum of Infant Age disaggregates 2019 322
PMTCT_STAT 25-29, Female 2019 901
PMTCT_STAT 25-29, Female 2019 4
PMTCT_STAT 25-29, Female, Known at Entry Positive 2019 103
PMTCT_STAT 25-29, Female, Newly Identified Negative 2019 772
PMTCT_STAT 25-29, Female, Newly Identified Negative 2019 4
PMTCT_STAT 25-29, Female, Newly Identified Positive 2019 26
PMTCT_STAT 30-34, Female 2019 697
PMTCT_STAT 30-34, Female 2019 3
PMTCT_STAT 30-34, Female, Known at Entry Positive 2019 81
PMTCT_STAT 30-34, Female, Newly Identified Negative 2019 599
PMTCT_STAT 30-34, Female, Newly Identified Negative 2019 3
PMTCT_STAT 30-34, Female, Newly Identified Positive 2019 17
PMTCT_STAT 35-39, Female 2019 288
PMTCT_STAT 35-39, Female 2019 1
PMTCT_STAT 35-39, Female, Known at Entry Positive 2019 34
PMTCT_STAT 35-39, Female, Newly Identified Negative 2019 248
PMTCT_STAT 35-39, Female, Newly Identified Negative 2019 1
PMTCT_STAT 35-39, Female, Newly Identified Positive 2019 6
PMTCT_STAT 40-49, Female 2019 81
PMTCT_STAT 40-49, Female, Known at Entry Positive 2019 9
PMTCT_STAT 40-49, Female, Newly Identified Negative 2019 71
PMTCT_STAT 40-49, Female, Newly Identified Positive 2019 1
PMTCT_STAT By Age (Numerator): : 15-19 2019 3
PMTCT_STAT By Age (Numerator): 15-19 2019 778
PMTCT_STAT By Age (Numerator): 20-24 2019 1,351
PMTCT_STAT By Age (Numerator): 20-24 2019 7
PMTCT_STAT By new negatives: 15-19 2019 3
PMTCT_STAT By new negatives: 20-24 2019 7
PMTCT_STAT By Number of known positives: 20-24 2019 6
PMTCT_STAT By Number of new negative: 15-19 2019 757
PMTCT_STAT By Number of new negative: 20-24 2019 1,311
PMTCT_STAT By Number of new positives: 15-19 2019 21
PMTCT_STAT By Number of new positives: 20-24 2019 34
PMTCT_STAT Number of new ANC and L&D clients 2019 4,096
PMTCT_STAT Number of new ANC and L&D clients 2019 18
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 4,096
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 18
PMTCT_STAT_den 25-29, Female 2019 901
PMTCT_STAT_den 25-29, Female 2019 4
PMTCT_STAT_den 30-34, Female 2019 697
PMTCT_STAT_den 30-34, Female 2019 3
PMTCT_STAT_den 35-39, Female 2019 288
PMTCT_STAT_den 35-39, Female 2019 1
PMTCT_STAT_den 40-49, Female 2019 81
PMTCT_STAT_den By Age (Denominator): <15-19 2019 778
PMTCT_STAT_den By Age (Denominator): 15-19 2019 3
PMTCT_STAT_den By Age (Denominator): 20-24 2019 1,351
PMTCT_STAT_den By Age (Denominator): 20-24 2019 7
PP_PREV 25-29, Female 2019 831
PP_PREV 25-29, Male 2019 1,485
PP_PREV 30-34, Female 2019 812
PP_PREV 30-34, Male 2019 1,481
PP_PREV 35-39, Female 2019 923
PP_PREV 35-39, Male 2019 1,644
PP_PREV 40-49, Female 2019 1,055
PP_PREV 40-49, Male 2019 1,887
PP_PREV Age/sex: 10-14 Female 2019 377
PP_PREV Age/sex: 15-19 Female 2019 2,139
PP_PREV Age/sex: 15-19 Male 2019 366
PP_PREV Age/sex: 20-24 Female 2019 1,781
PP_PREV Age/sex: 20-24 Male 2019 943
PP_PREV Age/sex: 50+ Female 2019 490
PP_PREV Age/sex: 50+ Male 2019 905
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2019 17,119
PP_PREV Sum of Age/Sex disaggregates 2019 7,001
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 3
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 22
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 3
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 39
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 67
TB_PREV Alternative TPT Regimen, Life-long ART, Already, Positive 2019 249
TB_PREV Alternative TPT Regimen, Life-long ART, Already, Positive 2019 12
TB_PREV Alternative TPT Regimen, Life-long ART, New, Positive 2019 29
TB_PREV Alternative TPT Regimen, Life-long ART, New, Positive 2019 2
TB_PREV By Age/Sex (Numerator): <15, Female 2019 18
TB_PREV By Age/Sex (Numerator): <15, Male 2019 11
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 171
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 10
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 84
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 4
TB_PREV IPT, Life-long ART, Already, Positive 2019 6
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 284
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 14
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 336
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 16
TB_PREV_den Alternative TPT Regimen, Life-long ART, Already, Positive 2019 293
TB_PREV_den Alternative TPT Regimen, Life-long ART, Already, Positive 2019 14
TB_PREV_den Alternative TPT Regimen, Life-long ART, New, Positive 2019 33
TB_PREV_den Alternative TPT Regimen, Life-long ART, New, Positive 2019 2
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 21
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 13
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 203
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 12
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 99
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 4
TB_PREV_den IPT, Life-long ART, Already, Positive 2019 9
TB_PREV_den IPT, Life-long ART, New, Positive 2019 1
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 6
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 45
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 6
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 94
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 151
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 151
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 6
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 45
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 6
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 94
TX_CURR 25-29, Female, Positive 2019 105
TX_CURR 25-29, Female, Positive 2019 5
TX_CURR 25-29, Male, Positive 2019 70
TX_CURR 25-29, Male, Positive 2019 3
TX_CURR 30-34, Female, Positive 2019 140
TX_CURR 30-34, Female, Positive 2019 7
TX_CURR 30-34, Male, Positive 2019 140
TX_CURR 30-34, Male, Positive 2019 7
TX_CURR 35-39, Female, Positive 2019 140
TX_CURR 35-39, Female, Positive 2019 7
TX_CURR 35-39, Male, Positive 2019 176
TX_CURR 35-39, Male, Positive 2019 8
TX_CURR 40-49, Female, Positive 2019 175
TX_CURR 40-49, Female, Positive 2019 11
TX_CURR 40-49, Male, Positive 2019 510
TX_CURR 40-49, Male, Positive 2019 25
TX_CURR Age/Sex: <1 2019 9
TX_CURR Age/Sex: <1-9 2019 57
TX_CURR Age/Sex: 1-9 2019 2
TX_CURR Age/Sex: 10-14 Female 2019 49
TX_CURR Age/Sex: 10-14 Female 2019 2
TX_CURR Age/Sex: 10-14 Male 2019 19
TX_CURR Age/Sex: 15-19 Female 2019 16
TX_CURR Age/Sex: 15-19 Male 2019 9
TX_CURR Age/Sex: 20-24 Female 2019 88
TX_CURR Age/Sex: 20-24 Female 2019 4
TX_CURR Age/Sex: 20-24 Male 2019 10
TX_CURR Age/Sex: 50+ Female 2019 53
TX_CURR Age/Sex: 50+ Female 2019 2
TX_CURR Age/Sex: 50+ Male 2019 124
TX_CURR Age/Sex: 50+ Male 2019 6
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 1,890
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 89
TX_CURR Sum of age/sex disaggregates 2019 25
TX_NEW 25-29, Female, Positive 2019 38
TX_NEW 25-29, Female, Positive 2019 8
TX_NEW 25-29, Male, Positive 2019 18
TX_NEW 30-34, Female, Positive 2019 10
TX_NEW 30-34, Male, Positive 2019 11
TX_NEW 35-39, Female, Positive 2019 11
TX_NEW 35-39, Male, Positive 2019 17
TX_NEW 40-49, Female, Positive 2019 7
TX_NEW 40-49, Male, Positive 2019 14
TX_NEW Breastfeeding status 2019 18
TX_NEW By Age/Sex: 1-9 2019 2
TX_NEW By Age/Sex: 10-14 Female 2019 2
TX_NEW By Age/Sex: 15-19 Female 2019 10
TX_NEW By Age/Sex: 15-19 Male 2019 2
TX_NEW By Age/Sex: 20-24 Female 2019 23
TX_NEW By Age/Sex: 20-24 Male 2019 7
TX_NEW By Age/Sex: 50+ Male 2019 7
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 179
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 8
TX_NEW Pregnancy status 2019 18
TX_NEW Sum of Age/Sex disaggregates 2019 51
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 80
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 1,698
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 3
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 68
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 10
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 2
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 33
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2019 3
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 934
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 44
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 7
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 142
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 21
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 441
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 3
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 67
TX_PVLS_den Denominator: Indication: Routine 2019 70
TX_PVLS_den Denominator: Indication: Routine 2019 1,476
TX_PVLS_den Denominator: Indication: Targeted 2019 10
TX_PVLS_den Denominator: Indication: Targeted 2019 222
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 8
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 4
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 196
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 9
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 173
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 8
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 381
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 17
TX_RET Numerator by Status: Breastfeeding 2019 37
TX_RET Numerator by Status: Breastfeeding 2019 2
TX_RET Numerator by Status: Pregnant 2019 37
TX_RET Numerator by Status: Pregnant 2019 2
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 424
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 19
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 9
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 5
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 218
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 11
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 192
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 8
TX_RET_den Denominator by Status: Breastfeeding 2019 42
TX_RET_den Denominator by Status: Breastfeeding 2019 2
TX_RET_den Denominator by Status: Pregnant 2019 42
TX_RET_den Denominator by Status: Pregnant 2019 2
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 1,890
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 89
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 114
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 5
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 77
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 4
TX_TB_den Denominator: By Aggregated Age/Sex: 15+, Female 2019 55
TX_TB_den Denominator: By Aggregated Age/Sex: 15+, Male 2019 25
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 1,152
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 547
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 58
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 4
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2019 3
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 16
TX_TB_den Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 4
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 77
TX_TB_den Life-long ART, Already, TB Screen - Negative, Positive 2019 1,646
TX_TB_den Life-long ART, Already, TB Screen - Negative, Positive 2019 78
TX_TB_den Life-long ART, Already, TB Screen - Positive, Positive 2019 49
TX_TB_den Life-long ART, Already, TB Screen - Positive, Positive 2019 2
TX_TB_den Life-long ART, New, TB Screen - Negative, Positive 2019 189
TX_TB_den Life-long ART, New, TB Screen - Negative, Positive 2019 9
TX_TB_den Life-long ART, New, TB Screen - Positive, Positive 2019 6
VMMC_CIRC 30-34, Male 2019 542
VMMC_CIRC 35-39, Male 2019 542
VMMC_CIRC 40-49, Male 2019 542
VMMC_CIRC By Age: 10-14 2019 677
VMMC_CIRC By Age: 15-19 2019 3,388
VMMC_CIRC By Age: 20-24 2019 3,388
VMMC_CIRC By Age: 25-29 2019 4,065
VMMC_CIRC By Age: 50+ 2019 406
VMMC_CIRC By circumcision technique: Surgical VMMC 2019 13,550
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2019 13,550
VMMC_CIRC Sum of age disaggregates (FY15-Current) 2019 11,924
VMMC_CIRC Sum of age disaggregates (Prior to FY15) 2019 7,859
Cross Cutting Budget Categories and Known Amounts Total: $205,000
Key Populations: Sex Workers $50,000
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Collection and use of strategic information on SWs and clients
Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Monitoring and evaluation of SW programs
Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: Gender Based Violence (GBV) $50,000
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Gender: Gender Equality $50,000
Changing harmful gender norms and promoting positive gender norms
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Promoting gender-related policies and laws that increase legal protection
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Increase gender-equitable access to income and productive resources, including education
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Equity in HIV prevention, care, treatment and support
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Condoms: Commodities $30,000
Water $25,000